Table 1 Characteristics of studies assessing sFlt-1 in first trimester of pregnancy
| Reference | Location | Study Design | Type of sample and gestational age at screening | Participants | Outcome(s) |
s-FLT1 Summary measure |
|---|---|---|---|---|---|---|
| Akolekar, 2010 | United Kingdom | nested case-control |
Plasma 11-13 weeks |
Singleton pregnancies Exclusions: hypertension but uncertainty about a diagnosis of preeclampsia (n = 30), preeclampsia but stored blood not available (n = 57) |
Preeclampsia < 34 weeks ≥ 34 weeks | median |
| Baumann, 2008 | Switzerland | case-control |
Serum 11-14 weeks |
Singleton pregnancies Exclusions: women with history of hypertensive disorders, immunological diseases, HELLP, or PE < 34 weeks | Preeclampsia | mean, median |
| Chaiworapongsa, 2005 | Chile | case-control |
Plasma 7-16 weeks | Singleton pregnancies. Exclusions: pregnancies with fetal anomaly or demise, vaginal bleeding, women with serious medical conditions, chronic hypertension, asthma requiring medication, or requiring the use of anti-platelet or non-steroidal anti-inflammatory drug. | Preeclampsia | mean |
| Erez, 2008 | Chile | nested case-control |
Plasma 6-15 weeks | Singleton pregnancies. |
SGA Preeclampsia (preterm and term) | median, OR |
| Eskild, 2008 | Norway | nested case-control |
Serum 4-12 weeks | Normotensive pregnant women only. | Excessive postpartum bleeding | mean |
| Lynch 2010 |
USA 2005-2008 | prospective cohort |
Serum 10-15 weeks |
Singleton pregnancies, women presenting for prenatal care Exclusions: intrauterine fetal loss, gestational hypertension | Preeclampsia | mean |
| Noori 2010 | United Kingdom | prospective cohort |
Serum 10-17 weeks | Singleton pregnancies from routine screening (n = 114) and an obstetric medicine clinic (n = 45) |
Preeclampsia, (preterm and term) Gestational hypertension | geometric mean |
| Rana S, 2007 |
USA 2001-2003 | nested case-control |
Serum 11-13 weeks |
Singleton pregnancies delivered > 20 weeks (livebirths) gestation. Exclusions: women with history of hypertension, hypertension 6 weeks postpartum, renal disease, or diabetes. | Preeclampsia | mean |
| Smith, 2007 |
Scotland 1997-99 | nested case-control |
Serum 10-14 weeks |
Singleton pregnancies. Exclusions: stillbirths due to congenital anomalies or rhesus disease. |
Preeclampsia SGA Preterm (extreme and moderate) Stillbirth | OR |
| Thadhani R, 2004 |
USA 2001-2003 | nested case-control |
Serum 8-14 weeks |
Singleton pregnancies > 20 weeks gestation. Exclusions: women with hypertension > 6 weeks postpartum, history of thyroid, liver, or chronic renal disease, or chronic hypertension. |
Preeclampsia, Gestational hypertension SGA | mean |
| Vatten LJ, 2007 |
Norway 1992-1994 | nested case-control |
Serum 4-12 weeks | Singleton pregnancies | Preeclampsia (preterm and term) | mean, OR |
| Wathen KA, 2006 |
Finland 2001-2002 | longitudinal case-control |
Serum 2-15 weeks |
Singleton pregnancies among Caucasian women Exclusions: women with history of hypertension, diabetes, chronic disease, or smoke > 5 cigarettes/day. |
Preeclampsia IUGR | median, OR |